Peter J. Rix

2.5k total citations
26 papers, 858 citations indexed

About

Peter J. Rix is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Genetics. According to data from OpenAlex, Peter J. Rix has authored 26 papers receiving a total of 858 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 7 papers in Molecular Biology and 7 papers in Genetics. Recurrent topics in Peter J. Rix's work include Estrogen and related hormone effects (7 papers), Prostate Cancer Treatment and Research (6 papers) and Radiopharmaceutical Chemistry and Applications (5 papers). Peter J. Rix is often cited by papers focused on Estrogen and related hormone effects (7 papers), Prostate Cancer Treatment and Research (6 papers) and Radiopharmaceutical Chemistry and Applications (5 papers). Peter J. Rix collaborates with scholars based in United States, Ireland and United Kingdom. Peter J. Rix's co-authors include Jay J. Ague, George H. Brimhall, Joachim Hampel, Christopher J. Lewis, W. E. Dietrich, Jeffrey H. Hager, Howard I. Scher, Edna Chow Maneval, Dana E. Rathkopf and Isan Chen and has published in prestigious journals such as Nature, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Peter J. Rix

25 papers receiving 826 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter J. Rix United States	14	271	189	131	125	120	26	858
Koichi Morita Japan	23	159 0.6×	289 1.5×	125 1.0×	71 0.6×	40 0.3×	108	1.7k
Suhui Yang South Korea	22	113 0.4×	382 2.0×	44 0.3×	265 2.1×	93 0.8×	41	969
Amanda Jones United States	13	148 0.5×	190 1.0×	236 1.8×	18 0.1×	72 0.6×	26	611
Yukio Koibuchi Japan	21	127 0.5×	442 2.3×	230 1.8×	27 0.2×	351 2.9×	132	1.5k
Jong Yeon Hwang South Korea	18	83 0.3×	577 3.1×	43 0.3×	426 3.4×	207 1.7×	68	1.1k
Hisashi Suzuki Japan	22	247 0.9×	210 1.1×	22 0.2×	118 0.9×	244 2.0×	79	1.4k
Xiaokun Ding China	21	46 0.2×	904 4.8×	428 3.3×	148 1.2×	190 1.6×	49	2.3k
Solomon Tadesse Ethiopia	18	265 1.0×	462 2.4×	42 0.3×	191 1.5×	369 3.1×	65	1.3k
Michiko Ichimasa Japan	11	121 0.4×	311 1.6×	19 0.1×	37 0.3×	60 0.5×	31	1.3k
Qianqian Guo China	17	87 0.3×	206 1.1×	116 0.9×	7 0.1×	186 1.6×	52	853

Countries citing papers authored by Peter J. Rix

Since Specialization

Citations

This map shows the geographic impact of Peter J. Rix's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter J. Rix with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter J. Rix more than expected).

Fields of papers citing papers by Peter J. Rix

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter J. Rix. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter J. Rix. The network helps show where Peter J. Rix may publish in the future.

Co-authorship network of co-authors of Peter J. Rix

This figure shows the co-authorship network connecting the top 25 collaborators of Peter J. Rix. A scholar is included among the top collaborators of Peter J. Rix based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter J. Rix. Peter J. Rix is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Govek, Steven P., Céline Bonnefous, Johnny Nagasawa, et al.. (2018). Selective estrogen receptor degraders with novel structural motifs induce regression in a tamoxifen-resistant breast cancer xenograft. Bioorganic & Medicinal Chemistry Letters. 29(3). 367–372. 7 indexed citations

Govek, Steven P., Johnny Nagasawa, Karensa Douglas, et al.. (2015). Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft. Bioorganic & Medicinal Chemistry Letters. 25(22). 5163–5167. 36 indexed citations

Dickler, Maura N., Aditya Bardia, Ingrid A. Mayer, et al.. (2015). Abstract CT231: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with estrogen receptor+ HER2-, advanced/metastatic breast cancer. Cancer Research. 75(15_Supplement). CT231–CT231. 21 indexed citations

Bardia, Aditya, Maura N. Dickler, Ingrid A. Mayer, et al.. (2015). Abstract P1-13-01: Phase I study of ARN-810, a novel and potent oral selective estrogen receptor degrader, in postmenopausal women with metastatic estrogen receptor positive (ER+), HER2- breast cancer. Cancer Research. 75(9_Supplement). P1–13. 1 indexed citations

Rix, Peter J., Andrew Vick, Geoffrey E. Barker, et al.. (2014). Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Nebulized Sodium Nitrite (AIR001) Following Repeat-Dose Inhalation in Healthy Subjects. Clinical Pharmacokinetics. 54(3). 261–272. 43 indexed citations

Tepper, Jeffrey S., Ricardo Ochoa, Peter J. Rix, et al.. (2014). A 26-Week Toxicity Assessment of AIR001 (Sodium Nitrite) by Inhalation Exposure in Rats and by Intravenous Administration in Dogs. International Journal of Toxicology. 33(3). 162–174. 4 indexed citations

Joseph, James D., Beatrice Darimont, Steven P. Govek, et al.. (2014). Abstract 4757: A novel class of selective estrogen receptors degraders regresses tumors in pre-clinical models of endocrine-resistant breast cancer. Cancer Research. 74(19_Supplement). 4757–4757. 1 indexed citations

Rathkopf, Dana E., Michael J. Morris, Josef J. Fox, et al.. (2013). Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer. Journal of Clinical Oncology. 31(28). 3525–3530. 204 indexed citations

Rathkopf, Dana E., Neal D. Shore, Emmanuel S. Antonarakis, et al.. (2012). A phase II study of the androgen signaling inhibitor ARN-509 in patients with castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology. 30(15_suppl). TPS4697–TPS4697. 15 indexed citations

10.

Rathkopf, Dana E., Michael J. Morris, Daniel C. Danila, et al.. (2012). A phase I study of the androgen signaling inhibitor ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 30(15_suppl). 4548–4548. 10 indexed citations

11.

Durón, Sergio G., Andrew B. Lindstrom, Céline Bonnefous, et al.. (2011). Heteroaromatic-aminomethyl quinolones: Potent and selective iNOS inhibitors. Bioorganic & Medicinal Chemistry Letters. 22(2). 1237–1241. 7 indexed citations

12.

Symons, Kent T., Mark E. Massari, John V. Anzola, et al.. (2010). Pharmacological Characterization of KLYP961, a Dual Inhibitor of Inducible and Neuronal Nitric-Oxide Synthases. Journal of Pharmacology and Experimental Therapeutics. 336(2). 468–478. 12 indexed citations

13.

Herbert, Mark R., Lena Staszewski, Charmagne Cayanan, et al.. (2010). Synthesis and SAR of 2-aryl-3-aminomethylquinolines as agonists of the bile acid receptor TGR5. Bioorganic & Medicinal Chemistry Letters. 20(19). 5718–5721. 49 indexed citations

14.

Payne, Joseph E., Céline Bonnefous, Kent T. Symons, et al.. (2010). Discovery of Dual Inducible/Neuronal Nitric Oxide Synthase (iNOS/nNOS) Inhibitor Development Candidate 4-((2-Cyclobutyl-1H-imidazo[4,5-b]pyrazin-1-yl)methyl)-7,8-difluoroquinolin-2(1H)-one (KD7332) Part 2: Identification of a Novel, Potent, and Selective Series of Benzimidazole-Quinolinone iNOS/nNOS Dimerization Inhibitors That Are Orally Active in Pain Models. Journal of Medicinal Chemistry. 53(21). 7739–7755. 52 indexed citations

15.

Vajda, Eric G., Francisco J. López, Peter J. Rix, et al.. (2008). Pharmacokinetics and Pharmacodynamics of LGD-3303 [9-Chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3 H-pyrrolo-[3,2-f]quinolin-7(6 H)-one], an Orally Available Nonsteroidal-Selective Androgen Receptor Modulator. Journal of Pharmacology and Experimental Therapeutics. 328(2). 663–670. 26 indexed citations

16.

Madhu, C, et al.. (1998). Penetration of Natural Prostaglandins and Their Ester Prodrugs and Analogs Across Human Ocular Tissues in Vitro. Journal of Ocular Pharmacology and Therapeutics. 14(5). 389–399. 12 indexed citations

17.

Madhu, C, et al.. (1997). Metabolic Deesterification of Tazarotene in Human Blood and Rat and HumanLiver Microsomes. Journal of Pharmaceutical Sciences. 86(8). 972–974. 29 indexed citations

18.

Madhu, C, et al.. (1997). The use of precision-cut rat lung slices for studying PGF2α metabolism. Environmental Toxicology and Pharmacology. 3(4). 251–256. 2 indexed citations

19.

Madhu, C, et al.. (1996). Effect of Benzalkonium Chloride/EDTA on the Ocular Bioavailability of Ketorolac Tromethamine following Ocular Instillation to Normal and De-epithelialized Corneas of Rabbits. Journal of Pharmaceutical Sciences. 85(4). 415–418. 14 indexed citations

20.

Brimhall, George H., Christopher J. Lewis, Jay J. Ague, et al.. (1988). Metal enrichment in bauxites by deposition of chemically mature aeolian dust. Nature. 333(6176). 819–824. 183 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact